Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A botanical combination therapy consisting of extracts from *Ganoderma lucidum* (Reishi mushroom) and *Crocus sativus* (Saffron), developed by the Peking University Hospital of Stomatology. This formulation is designed to target oral inflammatory conditions such as gingivitis and periodontal disease. *Ganoderma lucidum* contains bioactive triterpenoids and polysaccharides that exhibit significant anti-inflammatory and immunomodulatory properties, while saffron extract provides potent antioxidant effects through compounds like crocin and crocetin. The combination works synergistically to reduce dental plaque accumulation and alleviate gingival inflammation by modulating the local immune response and inhibiting pro-inflammatory signaling pathways, specifically targeting cytokines such as TNF-α and IL-6.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ganoderma lucidum + saffron extract.